Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04455906 · ClinicalTrials.gov registry record

Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism

A clinical trial of Atopic Dermatitis, sponsored by Boston Children's Hospital.

Recruiting
Registry status
111
Enrollment target
1
Study location

NCT04455906: Recruiting study of Atopic Dermatitis, sponsored by Boston Children's Hospital.

NCT04455906 is a study of Atopic Dermatitis that is actively recruiting participants, run by Boston Children's Hospital. The registered enrollment target is 111 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04455906, a study of Atopic Dermatitis, is actively recruiting participants, sponsored by Boston Children's Hospital.

RECRUITING
Registry status
111 participants
Enrollment target
1
Study location

Study Summary

This protocol is primarily looking to see if the IL-4Ra R576 polymorphism is associated with increased clinical, immunological and microbial markers of disease activity in patients with Atopic dermatitis.

Primary Outcome

validated assessment EASI score

Conditions Studied

Study Locations (1)

Massachusetts

  • Boston Children's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 111 participants
Start Date 2020-11-30
Est. Completion 2027-09-15
Boston Children's Hospital

462 total trials

What NCT04455906 shows while recruiting

NCT04455906 is an observational study that tracks outcomes without assigning an intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (82% lower).

The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 0 interventions.

NCT04455906 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04455906 about?

NCT04455906 is a clinical study titled "Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism". This protocol is primarily looking to see if the IL-4Ra R576 polymorphism is associated with increased clinical, immunological and microbial markers of disease activity in patients with Atopic dermatitis.

What is the current status of trial NCT04455906?

This trial is currently recruiting. The enrollment target is 111 participants. The study started on 2020-11-30. Estimated completion is 2027-09-15.

What conditions does trial NCT04455906 study?

This clinical trial studies the following conditions: Atopic Dermatitis.

Who is sponsoring clinical trial NCT04455906?

This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04455906 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Atopic Dermatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04455906's enrollment target sits among peer trials

111 81st of 150 higher than 70 of 150 other Atopic Dermatitis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03875716 · 111 participants · NA

    Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma

  • NCT04693468 · 111 participants · Phase 1

    Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

  • NCT05263050 · 111 participants · Phase 2

    Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

  • NCT05600842 · 111 participants

    De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04455906, the US trial registry maintained by the National Library of Medicine. NCT04455906 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.